Lipids and diabetic retinopathy

Expert Opinion on Biological Therapy

Volumn 12, Issue 1, 2012, Pages 93-105

  Lim, Laurence S ^a,b   Wong, Tien Y ^a,b,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical studies; Diabetic retinopathy; Lipid lowering therapy; Lipids

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BIOLOGICAL MARKER; CERAMIDE; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; RUBOXISTAURIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; AGED; ANIMALS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; FUNDUS OCULI; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MACULAR EDEMA; MIDDLE AGED; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RISK;

EID: 84055184273     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.641531     Document Type: Review

References (161)

1. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: The Singapore Malay Eye Study. Ophthalmology 2008;115:1869-75
2. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA 2007;298:902-16 (Pubitemid 47311296)
3. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58 (Pubitemid 38032183)
4. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997;115:873-7
5. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology1992;99:58-62
6. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991;98:1261-5
7. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63 (Pubitemid 38456292)
8. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes 1988;37:878-84 (Pubitemid 19043715)
9. Varma R, Macias GL, Torres M, et al. Biologic risk factors associated with diabetic retinopathy: The Los Angeles Latino Eye Study. Ophthalmology 2007;114:1332-40 (Pubitemid 47001493)
10. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. The UKPDs and the DCCT (ref 79) are pivotal clinical trials of medical therapy for DR.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
13. National Health and Medical Research Council. Guidelines for the Management of Diabetic Retinopathy. Commonwealth of Australia; 2008
14. American Academy of Ophthalmology Retina Panel PPPC. Diabetic retinopathy. American Academy of Ophthalmology (AAO); 2003
15. Yuen J, Clark A, Ng JQ, et al. Further survey of Australian ophthalmologist's diabetic retinopathy management: Did practice adhere to National Health and Medical Research Council guidelines? Clin Experiment Ophthalmol 2010;38:613-19
16. van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: The Hoorn Study. Diabetologia 2005;48:1300-6 (Pubitemid 41186094)
17. Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabet Med 2007;24:969-76 (Pubitemid 47301646)
18. Lambert J, Aarsen M, Donker AJ, Stehouwer CD. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:705-11 (Pubitemid 26153116)
19. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34:55-68 (Pubitemid 27261913)
20. Nagaoka T, Kuo L, Ren Y, et al. C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci 2008;49:2053-60
21. Dodson PM. Management of diabetic retinopathy: Could lipid-lowering be a worthwhile treatment modality? Eye (Lond) 2009;23:997-1003
22. Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009;32:1556-62
23. MEAD JF. Lipid metabolism. Annu Rev Biochem 1963;32:241-68
24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
25. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes ellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8 (Pubitemid 28112428)
26. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20 (Pubitemid 27143424)
27. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-19 (Pubitemid 29001188)
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
29. Moliterno DJ, Lange RA, Meidell RS, et al. Relation of plasma lipoproteina to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935-40 (Pubitemid 23264008)
30. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-19 Lim & Wong Expert Opin. Biol. Ther. (2012) 12(1) 101
31. Reed D, Benfante R. Lipid and lipoprotein predictors of coronary heart disease in elderly men in the Honolulu Heart Program. Ann Epidemiol 1992;2:29-34
32. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care 2003;26:16-23 (Pubitemid 36928989)
33. Agardh CD, Agardh E, Bauer B, Nilsson-Ehle P. Plasma lipids and plasma lipoproteins in diabetics with and without proliferative retinopathy. Acta Med Scand 1988;223:165-9 (Pubitemid 18071613)
34. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006;141:446-55
35. Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003;26:1731-7 (Pubitemid 36929112)
36. West KM, Erdreich LJ, Stober JA. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 1980;29:501-8 (Pubitemid 12180506)
37. Weber B, Burger W, Hartmann R, et al. Risk factors for the development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1986;29:23-9 (Pubitemid 16162737)
38. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/ EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-18 (Pubitemid 38868391)
39. Sjolie AK, Stephenson J, Aldington S, et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997;104:252-60 (Pubitemid 27088100)
40. Kissebah AH, Kohner EM, Lewis B, et al. Plasma-lipids and glucose/insulin relationship in non-insulin-requiring diabetics with and without retinopathy. Lancet 1975;1:1104-8
41. Rema M, Srivastava BK, Anitha B, et al. Association of serum lipids with diabetic retinopathy in urban South Indians-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med 2006;23:1029-36 (Pubitemid 44257950)
42. Dornan TL, Carter RD, Bron AJ, et al. Low density lipoprotein cholesterol: An association with the severity of diabetic retinopathy. Diabetologia 1982;22:167-70 (Pubitemid 12183673)
43. Miccoli R, Odello G, Giampietro O, et al. Circulating lipid levels and severity of diabetic retinopathy in type I diabetes mellitus. Ophthalmic Res 1987;19:52-6 (Pubitemid 17064250)
44. Kordonouri O, Danne T, Hopfenmuller W, et al. Lipid profiles and blood pressure: Are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr 1996;85:43-8 (Pubitemid 26043204)
45. Sinav S, Onelge MA, Onelge S, Sinav B. Plasma lipids and lipoproteins in retinopathy of type I (insulin-dependent) diabetic patients. Ann Ophthalmol 1993;25:64-6
46. Marshall G, Garg SK, Jackson WE, et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993;100:1133-9 (Pubitemid 23226807)
47. Jialal I, Joubert SM. The biochemical profile in Indian patients with non-insulin-dependent diabetes in the young with retinopathy. Diabete Metab 1985;11:262-5 (Pubitemid 15021692)
48. Klein BE, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol 1999;128:652-4 (Pubitemid 29528613)
49. Cohen RA, Hennekens CH, Christen WG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51 (Pubitemid 29328281)
50. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand 2004;82:443-8 (Pubitemid 39199446)
51. Ozer PA, Unlu N, Demir MN, et al. Serum lipid profile in diabetic macular edema. J Diabetes Complications 2009;23:244-8
52. Javadi MA, Katibeh M, Rafati N, et al. Prevalence of diabetic retinopathy in Tehran province: A population-based study. BMC Ophthalmol 2009;9:12
53. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84
54. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol 2007;52:180-95 (Pubitemid 46371493)
55. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32 (Pubitemid 14127839)
56. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-52 (Pubitemid 28093859)
57. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: The hoorn study. Diabetes Care 2002;25:1320-5 (Pubitemid 41071139)
58. Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : The atherosclerosis risk in communities study. Ophthalmology 2002;109:1225-34 (Pubitemid 34700911)
59. Miljanovic B, Glynn RJ, Nathan DM, et al. A prospective study of serum lipids and risk of diabetic macular edema intype 1 diabetes. Diabetes 2004;53:2883-92 (Pubitemid 39425914)
60. Raman R, Rani PK, Kulothungan V, et al. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology 2010;117:766-72
61. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-32 (Pubitemid 30061165)
62. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004;20:28-43 (Pubitemid 38196246)
63. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993;265:E783-93
64. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Lipids and diabetic retinopathy 102 Expert Opin. Biol. Ther. (2012) 12(1) differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63
65. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res 1999;18:79-82 (Pubitemid 29137563)
66. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997;273:H2442-51
67. Meyer DJ Jr, Huxley VH. Capillary hydraulic conductivity is elevated by cGMP-dependent vasodilators. Circ Res 1992;70:382-91
68. Mayhan WG. Role of nitric oxide in modulating permeability of hamster cheek pouch in response to adenosine 5'-diphosphate and bradykinin. Inflammation 1992;16:295-305
69. Sheetz MJ, Aiello LP, Shahri N, et al. Effect of ruboxistaurin (rbx) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: Results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 2011;31:1053-9
70. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010;51:4867-74
71. Schleicher ED,Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68 (Pubitemid 27414803)
72. Sakata N, Uesugi N, Takebayashi S, et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res 2001;49:466-75 (Pubitemid 32119564)
73. Fathallah L, Obrosova IG. Increased Retinal Lipid Peroxidation in early diabetes is not associated with ascorbate depletion or changes in ascorbate redox state. Exp Eye Res 2001;72:719-23 (Pubitemid 32977218)
74. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278:42027-35
75. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70
76. Nascimento NR, Lessa LM, Kerntopf MR, et al. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 2006;103:218-23 (Pubitemid 43076130)
77. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
78. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53 (Pubitemid 41817713)
79. ; The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
80. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-15
81. Brasacchio D, Okabe J, Tikellis C, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009;58:1229-36
82. El Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409-17
83. Tonna S, El Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms. Nat Rev Nephrol 2010;6:332-41
84. Kowluru A, Macdonald MJ. Protein phosphorylation in pancreatic islets: evidence for separate Ca2+ and cAMP-enhanced phosphorylation of two 57,000 Mr proteins. Biochem Biophys Res Commun 1984;118:797-804 (Pubitemid 14194793)
85. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010;13:797-805
86. Dos Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci 2011;52:8791-8
87. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000;28:3-8 (Pubitemid 30433242)
88. Kohner EM. The retinal blood flow in diabetes. Diabete Metab 1993;19:401-4 (Pubitemid 24039440)
89. Gardiner TA, Stitt AW, Anderson HR, Archer DB. Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. Br J Ophthalmol 1994;78:54-60 (Pubitemid 24035245)
90. Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995;79:362-7
91. Sharma NK, Gardiner TA, Archer DB. A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Ophthalmol 1985;100:51-60 (Pubitemid 15003411)
92. Gardiner TA, Stitt AW, Archer DB. Retinal vascular endothelial cell endocytosis increases in early diabetes. Lab Invest 1995;72:439-44
93. Stitt AW, Chakravarthy U, Archer DB, Gardiner TA. Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation. Diabetologia 1995;38:1271-5
94. Pugliese G, Tilton RG, Speedy A, et al. Vascular filtration function in galactose-fed versus diabetic rats: The role of polyol pathway activity. Metabolism 1990;39:690-7 (Pubitemid 20198260)
95. Skovbro M, Baranowski M, Skov-Jensen C, et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 2008;51:1253-60
96. Danesh J, Collins R, Peto R. Lipoprotein a and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5
97. Smolders B, Lemmens R, Thijs V. Lipoprotein a and stroke: Lim & Wong Expert Opin. Biol. Ther. (2012) 12(1) 103 a meta-analysis of observational studies. Stroke 2007;38:1959-66
98. Schreiner PJ, Morrisett JD, Sharrett AR, et al. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993;13:826-33 (Pubitemid 23164685)
99. Larsson LI, Alm A, Lithner F, et al. The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umea. Acta Ophthalmol Scand 1999;77:585-91 (Pubitemid 29476383)
100. Jenkins AJ, Steele JS, Janus ED, Best JD. Increased plasma apolipoproteina levels in IDDM patients with microalbuminuria. Diabetes 1991;40:787-90
101. Gazzaruso C, Garzaniti A, Buscaglia P, et al. Lipoproteina levels and apolipoproteina polymorphism in type 1 diabetes mellitus: Relationships to microvascular and neurological complications. Acta Diabetol 1998;35:13-18 (Pubitemid 28306249)
102. Maioli M, Tonolo G, Pacifico A, et al. Raised serum apolipoprotein a in active diabetic retinopathy. Diabetologia 1993;36:88-90 (Pubitemid 23018342)
103. Verrotti A, Lobefalo L, Chiarelli F, et al. Lipids and lipoproteins in diabetic adolescents and young adults with retinopathy. Eye (Lond) 1997;11(Pt 6):876-81 (Pubitemid 28024961)
104. Guerci B, Meyer L, Sommer S, et al. Severity of diabetic retinopathy is linked to lipoprotein a in type 1 diabetic patients. Diabetes Metab 1999;25:412-18
105. Winocour PH, Bhatnagar D, Ishola M, et al. Lipoprotein a and microvascular disease in type 1 (insulin-dependent) diabetes. Diabet Med 1991;8:922-7
106. Willems D, Dorchy H, Dufrasne D. Serum lipoprotein a in type 1 diabetic children and adolescents: Relationships with HbA1c and subclinical complications. Eur J Pediatr 1996;155:175-8 (Pubitemid 26053358)
107. Ritter MM, Loscar M, Richter WO, Schwandt P. Lipoproteina in diabetes mellitus. Clin Chim Acta 1993;214:45-54
108. Maser RE, Usher D, Becker DJ, et al. Lipoproteina concentration shows little relationship to IDDM complications inthe Pittsburgh Epidemiology of Diabetes Complications Study cohort. Diabetes Care 1993;16:755-8 (Pubitemid 23127182)
109. Boemi M, Sirolla C, Amadio L, et al. Lipoproteina and retinopathy in IDDM and NIDDM patients. Diabetes Care 1997;20:115
110. Haffner SM, Klein BE, Moss SE, Klein R. Lpa is not related to retinopathy in diabetic subjects. Eur J Ophthalmol 1995;5:119-23
111. Suehiro M, Ohkubo K, Kato H, et al. Analyses of serum lipoproteina and the relation to phenotypes and genotypes of apolipoproteina in type 2 diabetic patients with retinopathy. Exp Clin Endocrinol Diabetes 2002;110:319-24 (Pubitemid 35278484)
112. Heesen BJ, Wolffenbuttel BH, Leurs PB, et al. Lipoproteina levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest 1993;23:580-4 (Pubitemid 23283067)
113. Suzuki T, Oba K, Igari Y, et al. Relation of apolipoprotein a phenotypes to diabetic retinopathy in elderly type 2 diabetes. J Nippon Med Sch 2002;69:31-8
114. Kim CH, Park HJ, Park JY, et al. High serum lipoproteina levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy. Diabetes Care 1998;21:2149-51
115. Morisaki N, Yokote K, Tashiro J, et al. Lipoproteina is a risk factor for diabetic retinopathy in the elderly. J Am Geriatr Soc 1994;42:965-7 (Pubitemid 24280371)
116. Onuma T, Kikuchi T, Shimura M, et al. Lipoproteina as an independent risk factor for diabetic retinopathy in male patients in non-insulin-dependent diabetes mellitus. Tohoku J Exp Med 1994;173:209-16
117. Deepa R, Mohan A, Rema M, et al. Lipoproteina in South Indian type 2 diabetic subjects in relation to diabetic vascular complications. J Assoc Physicians India 2002;50:657-61
118. Durlach V, Gillery P, Bertin E, et al. Serum lipoprotein a concentrations in a population of 819 non-insulin-dependent diabetic patients. Diabetes Metab 1996;22:319-23 (Pubitemid 26323439)
119. Mondorf UF, Piiper A, Herrero M, et al. Lipoproteina stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins. Kidney Int 1999;55:1359-66 (Pubitemid 29157134)
120. Mondorf UF, Piiper A, HerreroM, et al. Lipoprotein a stimulates mitogen activated protein kinase in human mesangial cells. FEBS Lett 1998;441:205-8 (Pubitemid 29027896)
121. Wanner C, Greiber S, Kramer-Guth A, et al. Lipids and progression of renal disease: Role of modified low density lipoprotein and lipoproteina. Kidney Int Suppl 1997;63:S102-6 (Pubitemid 28020445)
122. Jenkins AJ, Rowley KG, Lyons TJ, et al. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004;10:3395-418 (Pubitemid 39276625)
123. Marcovina SM, Koschinsky ML. Evaluation of lipoproteina as a prothrombotic factor: Progress from bench to bedside. Curr Opin Lipidol 2003;14:361-6 (Pubitemid 36951901)
124. Scanu AM. The role of lipoproteina in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep 2001;3:385-90
125. Kronenberg F, Utermann G, Dieplinger H. Lipoproteina in renal disease. Am J Kidney Dis 1996;27:1-25
126. Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011;34:474-9
127. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14 (Pubitemid 8110784)
128. Miller GJ, Miller NE. Plasma-highdensity- lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1:16-19
129. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72 (Pubitemid 39390578)
130. Simo R, Garcia-Ramirez M, Higuera M, Hernandez C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol 2009;147:319-25
131. Simo R, Higuera M, Garcia-Ramirez M, et al. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol 2008;126:1076-81
132. Tserentsoodol N, Gordiyenko NV, Pascual I, et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 2006;12:1319-33 Lipids and diabetic retinopathy 104 Expert Opin. Biol. Ther. (2012) 12(1) (Pubitemid 44688463)
133. Tyroler HA. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC coronary primary prevention trial. Am J Cardiol 1984;54:14C-9C (Pubitemid 14073502)
134. Kannel WB, Gordon T, Castelli WP. Role of lipids and lipoprotein fractions in atherogenesis: The Framingham study. Prog Lipid Res 1981;20:339-48
135. Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:2679-85
136. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969;18:285-91
137. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1974;94:554-62
138. Duncan LJ, Cullen JF, Ireland JT, et al. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968;17:458-67
139. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-82 (Pubitemid 38446682)
140. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11 (Pubitemid 34170743)
141. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: Is there a place for lipid lowering therapy? Eye (Lond) 2002;16:689-93 (Pubitemid 35460544)
142. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol1991;112:385-91
143. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96 (Pubitemid 39140624)
144. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91 (Pubitemid 351214285)
145. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomized controlled trial. Lancet 2007;370:1687-97 The landmark FIELD and ACCORD (ref 146) trials both demonstrated the benefits of fenofibrate in preventing DR progression. (Pubitemid 350100775)
146. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010;376:419-30
147. Ridker PM, Macfadyen J, Libby P, Glynn RJ. Relation of baseline High-Sensitivity C-Reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010;106:204-9
148. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97:33A-41A (Pubitemid 43139718)
149. Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370-8 (Pubitemid 40543311)
150. Jackevicius CA, Tu JV, Ross JS, et al. Use of fibrates in the United States and Canada. JAMA 2011;305:1217-24
151. Dowd TC, Howard-Williams J, Thursfield V, et al. Diabetic retinopathy: Different risk factors for exudates and haemorrhages. Int Ophthalmol 1986;9:11-15 (Pubitemid 16082540)
152. Shen LQ, Child A, Weber GM, et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 2008;126:793-9 (Pubitemid 351831328)
153. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-70 (Pubitemid 44620399)
154. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147:583-6
155. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-61
156. Vandongen R, Mori TA, Codde JP, et al. Hypercholesterolaemic effect of fish oil in insulin-dependent diabetic patients. Med J Aust 1988;148:141-3
157. Kaushik S, Wang JJ, Flood V, et al. Frequency of fish consumption, retinal microvascular signs and vascular mortality. Microcirculation 2008;15:27-36
158. Hammes HP, Weiss A, Fuhrer D, et al. Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids. Diabetologia 1996;39:251-5 (Pubitemid 26064820)
159. Janknecht P, Schumann M, Hansen LL. Reduction of retinal exudates in diabetic retinopathy after heparin-induced extracorporal LDL-precipitation (HELP). A case report. Eur J Ophthalmol 1996;6:340-2 (Pubitemid 26346066)
160. Lloyd CE, Klein R, Maser RE, et al. The progression of retinopathy over 2 years: The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications 1995;9:140-8
161. Funatsu H, Shimizu E, Noma H, et al. Association between serum lipoprotein a level and progression of non-proliferative diabetic retinopathy in Type 2 diabetes. Acta Ophthalmol 2009;87:501-5